Public Accountability for Private Action

Sharing what we're doing and learning has long been a priority at Wallace, and the past several years have seen a growing number of foundations also taking steps to "open their doors and windows." Some aspects are easy to report on: program initiatives, the purpose of individual grants to specific organizations, a foundation's overall financial health. Less easy to measure, and more difficult to discuss publicly, are the results of a foundation's work. What progress have we made toward our ambitious social change goals? How do we know? How can we talk about what didn't work? These are the issues that we and other foundations are wrestling with

How Are We Doing? One Foundation's Efforts to Gauge its Effectiveness

Provides an overview of the path the Wallace Foundation staff followed in an effort to develop a tool for measuring their own organizational effectiveness. Includes lessons learned

Arts for All: Connecting to New Audiences

Summarizes discussions among arts leaders and experts at an April 2008 conference on how to build arts appreciation and participation in a new environment through better marketing, new technology, and audience research

Education Leadership: A Bridge to School Reform

Contains highlights from the foundation's 2007 national conference, including commentary on the foundation's education leadership initiative and extended excerpts from two of the conference's keynote speakers

Discovery of a Potent and Selective DGAT1 Inhibitor with a Piperidinyl-oxy-cyclohexanecarboxylic Acid Moiety

We report the discovery of a novel series of DGAT1 inhibitors in the benzimidazole class with a piperdinyl-oxy-cyclohexanecarboxylic acid moiety. This novel series possesses significantly improved selectivity against the A_2A receptor, no ACAT1 off-target activity at 10 μM, and higher aqueous solubility and free fraction in plasma as compared to the previously reported pyridyl-oxy-cyclohexanecarboxylic acid series. In particular, <b>5B</b> was shown to possess an excellent selectivity profile by screening it against a panel of more than 100 biological targets. Compound <b>5B</b> significantly reduces lipid excursion in LTT in mouse and rat, demonstrates DGAT1 mediated reduction of food intake and body weight in mice, is negative in a 3-strain Ames test, and appears to distribute preferentially in the liver and the intestine in mice. We believe this lead series possesses significant potential to identify optimized compounds for clinical development